Chemotherapy-free treatment in patients with follicular lymphoma

References

• Lister TA. Improved survival for patients with follicular lymphoma. J Clin Oncol 2005;23(22):4830-1
   PubMedGoogle Scholar
• Liu Q, Fayad L, Cabanillas F, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 2006;24(10):1582-9
   PubMed Web of Science ®Google Scholar
• Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23(22):5019-26
   PubMed Web of Science ®Google Scholar
• Cabanillas F. Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm? J Clin Oncol 2013;31(1):14-16
   PubMedGoogle Scholar
• Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25(15):1986-92
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26(28):4579-86
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106(12):3725-32
   PubMed Web of Science ®Google Scholar
• Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377(9759):42-51
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz S-FH, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004;103(12):4416-23
   PubMed Web of Science ®Google Scholar
• Salles G, Ghesquières H. Current and future management of follicular lymphoma. Int J Hematol 2012;96(5):544-51
   PubMedGoogle Scholar
• Haines IE. Should the paradigm shift for low-grade follicular non-Hodgkin lymphoma Be toward less therapy? J Clin Oncol 2013;31(14):1797-8
   PubMedGoogle Scholar
• Bachy E, Brice P, Delarue R, et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d’etude des lymphomes de l’adulte. J Clin Oncol 2010;28(5):822-9
   PubMedGoogle Scholar
• Gyan E, Foussard C, Bertrand P, et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009;113(5):995-1001
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Vitolo U, Kimby E, et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013;24(3):561-76
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas. J Natl Compr Canc Netw 2010;8(3):288-334
   PubMed Web of Science ®Google Scholar
• Michallet A-SA, Lebras LL, Bauwens DD, et al. Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy? J Hematol Oncol 2013;6(1):45
   PubMedGoogle Scholar
• Friedberg JW, Byrtek M, Link BK, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 2012;30(27):3368-75
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-López AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 1997;15(10):3266-74
   PubMed Web of Science ®Google Scholar
• Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84(8):2457-66
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16(8):2825-33
   PubMed Web of Science ®Google Scholar
• Feuring-Buske M, Kneba M, Unterhalt M, et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000;79(9):493-500
   PubMed Web of Science ®Google Scholar
• Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1999;10(6):655-61
   PubMed Web of Science ®Google Scholar
• Davis TA, White CA, Grillo-López AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17(6):1851-7
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Grillo-López AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1998;9(9):995-1001
   PubMed Web of Science ®Google Scholar
• Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97(1):101-6
   PubMed Web of Science ®Google Scholar
• Colombat P, Brousse N, Salles G, et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up. Ann Oncol 2012;23(9):2380-5
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin’s lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 2005;23(6):1103-8
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Burris HA3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000;95(10):3052-6
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Litchy S, Burris HA3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin’s lymphoma. J Clin Oncol 2002;20(20):4261-7
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005;16(10):1675-82
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 2014;15(4):424-35
   PubMed Web of Science ®Google Scholar
• Kahl BS, Hong F, Williams ME, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol 2014;32(28):3096-102
   PubMed Web of Science ®Google Scholar
• Martinelli G, Hitz F, Mingrone W, et al. Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: results of the randomized phase III trial SAKK 35/03. Blood 2013;122(21):508-8
   Google Scholar
• Solal-Céligny P, Bellei M, Marcheselli L, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 2012;30(31):3848-53
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18(17):3135-43
   PubMed Web of Science ®Google Scholar
• Cartron G. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104(9):2635-42
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008;14(5):1561-70
   PubMed Web of Science ®Google Scholar
• Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009;113(20):4885-93
   PubMed Web of Science ®Google Scholar
• Jäger U, Fridrik M, Zeitlinger M, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 2012;97(9):1431-8
   PubMed Web of Science ®Google Scholar
• Daydé D, Ternant D, Ohresser M, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 2009;113(16):3765-72
   PubMed Web of Science ®Google Scholar
• Dall’Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64(13):4664-9
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99(3):754-8
   PubMed Web of Science ®Google Scholar
• Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011;118(2):358-67
   PubMed Web of Science ®Google Scholar
• Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012;119(22):5126-32
   PubMed Web of Science ®Google Scholar
• Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012;119(22):5118-25
   PubMed Web of Science ®Google Scholar
• Salles GA, Morschhauser F, Solal-Celigny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013;31(23):2920-6
   PubMed Web of Science ®Google Scholar
• Sehn LH, Goy A, Offner FC, et al. Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study. Blood 2011;118:abstract 269
   Google Scholar
• Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008;111(12):5486-95
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Fayad L, Delwail V, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 2012;119(16):3698-704
   PubMed Web of Science ®Google Scholar
• Negrea GO, Elstrom R, Allen SL, et al. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin’s lymphoma. Haematologica 2011;96(4):567-73
   PubMedGoogle Scholar
• Morschhauser F, Leonard JP, Fayad L, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II results. J Clin Oncol 2009;27(20):3346-53
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Deng C, Amengual JE, et al. A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab. J Clin Oncol 2014;32(5s Suppl):abstract 8524
   Google Scholar
• Cartron G, Zhao-Yang L, Baudard M, et al. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 2008;26(16):2725-31
   PubMed Web of Science ®Google Scholar
• Gluck WL, Hurst D, Yuen A, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004;10(7):2253-64
   PubMed Web of Science ®Google Scholar
• Kimby E, Ostenstad B, de Nully Brown P, et al. Rituximab (R) in combination with interferon-a2a (ifn) versus single r in patients with follicular or other cd20+ low-grade (indolent) lymphoma. final results from a randomized phase iii study from the nordic lymphoma group. ASH Annual Meeting Abstracts 2012;120(21):794
   Google Scholar
• Staak JO, Colcher D, Lauder S, et al. The novel de-immunized anti-cd20-il-2 immunocytokine di-leu16-il-2 is effective in scid mice bearing rituximab-resistant human lymphoma xenografts. ASH Annual Meeting Abstracts 2004;104(11):3288
   Google Scholar
• Xuan C, Steward KK, Timmerman JM, Morrison SL. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 2010;115(14):2864-71
   PubMedGoogle Scholar
• Nordstrom DL, Rossi EA, Goldenberg DM, Chang C-H. First bispecific antibody immunocytokine (anti-cd20/hla-dr-interferon-a2b) is highly toxic for human lymphoma cells in vitro. ASH Annual Meeting Abstracts 2009;114(22):1695
   Google Scholar
• Peng W, Zhang X, Mohamed N, et al. A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation. Cancer Immunol Immunother 2005;54(12):1172-9
   PubMedGoogle Scholar
• Modak S, Koehne G, Vickers A, et al. Rituximab therapy of lymphoma is enhanced by orally administered (1-->3), (1-->4)-D-beta-glucan. Leuk Res 2005;29(6):679-83
   PubMedGoogle Scholar
• Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin’s lymphoma. J Clin Oncol 2003;21(16):3051-9
   PubMed Web of Science ®Google Scholar
• Leonard JP, Schuster SJ, Emmanouilides C, et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008;113(10):2714-23
   PubMed Web of Science ®Google Scholar
• Strauss SJ, Morschhauser F, Rech J, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol 2006;24(24):3880-6
   PubMed Web of Science ®Google Scholar
• Grant BW, Jung SH, Johnson JL, et al. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer 2013;119(21):3797-804
   PubMed Web of Science ®Google Scholar
• Byrd JC, Pagel JM, Awan FT, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood 2014;123(9):1302-8
   PubMed Web of Science ®Google Scholar
• Stein R, Mattes MJ, Cardillo TM, et al. CD74: a New Candidate Target for the Immunotherapy of B-Cell Neoplasms. Clin Cancer Res 2007;13(18):5556s-63s
   PubMed Web of Science ®Google Scholar
• Alinari L, Yu B, Christian BA, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood 2011;117(17):4530-41
   PubMed Web of Science ®Google Scholar
• Kaufman JL, Niesvizky R, Stadtmauer EA, et al. Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma. J Clin Oncol 2009;27(15S):8593
   Google Scholar
• Christian B, Alinari L, Earl CT, et al. A phase I study of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, in patients with relapsed and refractory B-cell non-Hodgkin’s lymphoma. Blood 2010;116:abstract 2788
   Google Scholar
• Smith MR, Jin F, Joshi I. Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line. Br J Haematol 2014;165(1):151-3
   PubMed Web of Science ®Google Scholar
• Rossi EA, Chang C-H, Cardillo TM, et al. Bispecific anti-CD20/anti-CD22 antibodies with potent lymphoma cytotoxicity. ASH Annual Meeting Abstracts 2008;112(11):1591
   Google Scholar
• Tuscano JM, Ma Y, Martin SM, et al. The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone. Cancer Immunol Immunother 2011;60(6):771-80
   PubMedGoogle Scholar
• Viardot A, Goebeler M, Scheele JS, et al. Treatment of patients with non-Hodgkin lymphoma (NHL) with CD19/CD3 bispecific antibody blinatumomab (MT103): double-step dose increase to continuous infusion of 60 {micro}g/m2/d is tolerable and highly effective. ASH Annual Meeting Abstracts 2010;116(21):2880
   Google Scholar
• Gupta P, Goldenberg DM, Rossi EA, et al. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood 2012;119(16):3767-78
   PubMedGoogle Scholar
• Li D, Poon KA, Yu S-F, et al. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther 2013;12(7):1255-65
   PubMedGoogle Scholar
• Advani RH, Chen AI, Lebovic D. Final results of a phase I study of the anti-CD22 antibody-drug conjugate (ADC) DCDT2980S with or without rituximab (RTX) in patients (Pts) with relapsed or refractory (R/R) B-Cell non-Hodgkin’s lymphoma (NHL). Blood 2013;122;abstract 4399
   Google Scholar
• Morschhauser F, Flinn I, Advani RH, et al. Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). ASCO Meeting Abstracts 2014;32(15_Suppl):8519
   Google Scholar
• Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-hodgkin lymphoma: results of a Phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 2013;31(5):573-83
   PubMed Web of Science ®Google Scholar
• Ribrag V, Dupuis J, Tilly H, et al. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2014;20(1):213-20
   PubMed Web of Science ®Google Scholar
• Witzig TE, Fishkin P, Gordon LI, et al. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk Lymphoma 2011;52(7):1188-99
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352(5):441-9
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Vose JM, Czuczman MS, et al. Phase II multicenter study of the safety and efficacy of single-agent lenalidomide in subjects with relapsed/refractory mantle cell lymphoma: long-term follow-up analysis of the NHL-003 Study. ASH Annual Meeting Abstracts 2012;120(21):2738
   Google Scholar
• Myklebust JH, Irish JM, Brody J, et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 2013;121(8):1367-76
   PubMed Web of Science ®Google Scholar
• Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014;15(1):69-77
   PubMed Web of Science ®Google Scholar
• Study of nivolumab in subjects with relapsed or refractory follicular lymphoma (FL) (CheckMate 140). Available from: http://clinicaltrials.gov/ct2/show/NCT02038946
   Google Scholar
• A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013). Available from: http://clinicaltrials.gov/ct2/show/NCT01953692
   Google Scholar
• Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2009;15(20):6446-53
   PubMed Web of Science ®Google Scholar
• Benson DMJr, Hofmeister CC, Padmanabhan S, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012;120(22):4324-33
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Thielens A, Marabelle A, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 2014;123(5):678-86
   PubMed Web of Science ®Google Scholar
• Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010;142(5):699-713
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Goldstein MJ, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011;117(8):2423-32
   PubMed Web of Science ®Google Scholar
• Houot R, Goldstein MJ, Kohrt HE, et al. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood 2009;114(16):3431-8
   PubMed Web of Science ®Google Scholar
• Safety, Tolerability, pharmacokinetics, and immunoregulatory study of urelumab (bms-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory b-cell non-hodgkin’s lymphoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01471210
   Google Scholar
• Combination study of urelumab and rituximab in patients with b-cell non-hodgkins lymphoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01775631
   Google Scholar
• Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351(21):2159-69
   PubMed Web of Science ®Google Scholar
• De Jong D, Koster A, Hagenbeek A, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009;94(1):70-7
   PubMedGoogle Scholar
• Ramsay AG, Clear AJ, Kelly G, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009;114(21):4713-20
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008;14(14):4650-7
   PubMed Web of Science ®Google Scholar
• Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009;84(9):553-9
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005;11(16):5984-92
   PubMed Web of Science ®Google Scholar
• Gaidarova S, Li J, Corral LG, et al. Lenalidomide alone and in combination with rituximab enhances nk cell immune synapse formation in chronic lymphocytic leukemia (cll) cells in vitro through activation of rho and rac1 gtpases. ASH Annual Meeting Abstracts 2009;114(22):3441
   Google Scholar
• Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol 2009;27(32):5404-9
   PubMed Web of Science ®Google Scholar
• Leonard J, Jung SH, Johnson JL, et al. CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. J Clin Oncol 2012;30(15 Suppl):8000
   Google Scholar
• Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014;15(12):1311-18
   PubMed Web of Science ®Google Scholar
• Rawal S, Fowler N, Zhang M, et al. Activation of T and NK cells following lenalidomide therapy in patients with follicular lymphoma. ASH Annual Meeting Abstracts 2012;120(21):2766
   Google Scholar
• Martin P, Sin-Ho J, Johnson J. CALGB 50803 (Alliance): a phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Meeting Abstracts 2014. Available from: www.index.html. [Last accessed on 8 June 2014]
   Google Scholar
• Kimby E, Martinelli G, Ostenstad B. Rituximab plus lenalidomide improves the complete remission rate in comparison with rituximab monotherapy in untreated follicular lymphoma patients in need of therapy. primary endpoint analysis of the randomized Phase-2 Trial SAKK 35/10. Blood 2014;124;abstract 799
   Google Scholar
• Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma (RELEVANCE). Available from: http://clinicaltrials.gov/ct2/show/NCT01476787
   Google Scholar
• Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327(17):1209-15
   PubMed Web of Science ®Google Scholar
• Redfern CH, Guthrie TH, Bessudo A, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin’s lymphoma resulting in durable clinical responses. J Clin Oncol 2006;24(19):3107-12
   PubMed Web of Science ®Google Scholar
• Koc ON, Redfern C, Wiernik PH, et al. Continued late conversion to complete remission (cr/cru) and durability of remission (dur) in pts with b-cell follicular lymphoma (fl) treated with rituximab followed by mitumprotimut-T (Id-KLH, FavId(R)) Active Immunotherapy. ASH Annual Meeting Abstracts 2007;110(11):3427
   Google Scholar
• Freedman A, Neelapu SS, Nichols C, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol 2009;27(18):3036-43
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Neelapu SS, Gause BL, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011;29(20):2787-94
   PubMed Web of Science ®Google Scholar
• Levy R, Ganjoo KN, Leonard JP, et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol 2014;32(17):1797-803
   PubMed Web of Science ®Google Scholar
• Fowler NH, Advani RH, Sharman J, et al. The bruton’s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. ASH Annual Meeting Abstracts 2012;120(21):156
   Google Scholar
• Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01849263
   Google Scholar
• Study of the Bruton’s Tyrosine Kinase Inhibitor in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01980654
   Google Scholar
• Rituximab, Lenalidomide, and Ibrutinib in treating patients with previously untreated stage ii-iv follicular lymphoma. Available from: http://clinicaltrials.gov/ct2/show/NCT01829568
   Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014;123(22):3406-13
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370(11):1008-18
   PubMed Web of Science ®Google Scholar
• Wagner-Johnston N, Gopal A, Kahl B. Patient-reported outcomes data from a phase 2 study of idelalisib in patients with refractory indolent B-cell non-Hodgkin lymphoma (iNHL). Meeting Abstracts J Clin Oncol 2014;32(Suppl):abstrct e19554
   Google Scholar
• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (Yosemite). Available from: http://clinicaltrials.gov/ct2/show/NCT01732913
   Google Scholar
• Flinn IW, Horwitz SM, Patel M, et al. Clinical Safety and Activity in a Phase 1 Trial of IPI-145, a Potent Inhibitor of Phosphoinositide-3-Kinase-{delta},{gamma}, in Patients with Advanced Hematologic Malignancies. ASH Annual Meeting Abstracts 2012;120(21):3663
   Google Scholar
• Morschhauser F, Bron D, Bouabdallah K, et al. Preliminary results of a phase ii study of single agent bay 80-6946, a Novel PI3K Inhibitor, In Patients With relapsed/refractory, indolent or aggressive Lymphoma. Blood 2013;122(21):87-7
   Google Scholar
• Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin’s lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol 2010;28(31):4740-6
   PubMed Web of Science ®Google Scholar
• Fruchon S, Kheirallah S, Al Saati T, et al. Involvement of the Syk–mTOR pathway in follicular lymphoma cell invasion and angiogenesis. Leukemia 2012;26(4):795-805
   PubMedGoogle Scholar
• Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115(13):2578-85
   PubMed Web of Science ®Google Scholar
• Coiffier B, Osmanov EA, Hong X, et al. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 2011;12(8):773-84
   PubMed Web of Science ®Google Scholar
• Davids matthew S, Seymour JF, Gerecitano J. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. J Clin Oncol 2014;32(5s Suppl):abstract 8522
   Google Scholar
• Guo S, Chan JKC, Iqbal J, et al. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations. Clin Cancer Res 2014;20(12):3078-86
   PubMedGoogle Scholar
• Bödör C, Grossmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013;122(18):3165-8
   PubMed Web of Science ®Google Scholar
• McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012;492(7427):108-12
   PubMed Web of Science ®Google Scholar
• Trotman J, Fournier M, Lamy T, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clinical Oncol 2011;29(23):3194-200
   PubMed Web of Science ®Google Scholar